Sara Bonstein Sells 748 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein sold 748 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the completion of the sale, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at approximately $12,469,365.72. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Thursday, January 8th, Sara Bonstein sold 1,447 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $252,023.99.
• On Wednesday, January 7th, Sara Bonstein sold 1,678 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $293,767.46.
• On Tuesday, January 6th, Sara Bonstein sold 1,517 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $262,941.61.

Insmed Trading Down 0.9%

Shares of Insmed stock opened at $151.03 on Friday. The company has a 50-day moving average of $176.03 and a two-hundred day moving average of $159.60. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The stock has a market cap of $32.21 billion, a PE ratio of -24.40 and a beta of 1.11.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Large institutional holders remain significant and have been increasing positions, which supports structural demand and can limit downside. MarketBeat Institutional Holdings
• Positive Sentiment: Analyst coverage is strongly skewed to Buy/Strong Buy with an average price target well above the current trading level, implying upside if upcoming results and guidance meet expectations. MarketBeat Analyst Coverage
• Neutral Sentiment: Insmed set its Q4 and full‑year 2025 results release and conference call for Feb. 19 — a concrete near‑term catalyst that will provide revenue, margin and guidance data investors will use to re‑rate the stock. PR Newswire: Earnings Date
• Negative Sentiment: Clustered insider sales: multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and another officer) sold shares on Feb. 3. Such concentrated selling by leadership can be interpreted negatively and likely contributed to intraday weakness. InsiderTrades: Insider Sales
• Negative Sentiment: Pattern risk: the CFO and other officers had earlier sales in January, creating a sequence of executive trims this quarter rather than isolated trades; that pattern may increase short‑term selling pressure or investor caution ahead of Feb. 19. SEC Form 4 (CEO/CFO Sales)

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently modified their holdings of the company. EULAV Asset Management acquired a new stake in Insmed during the third quarter worth approximately $12,961,000. Resolute Capital Asset Partners LLC purchased a new position in shares of Insmed during the 2nd quarter worth $2,748,000. Nisa Investment Advisors LLC boosted its holdings in shares of Insmed by 374.6% during the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after purchasing an additional 8,261 shares during the last quarter. Calamos Advisors LLC grew its position in shares of Insmed by 53.4% in the third quarter. Calamos Advisors LLC now owns 35,215 shares of the biopharmaceutical company’s stock valued at $5,071,000 after purchasing an additional 12,263 shares during the period. Finally, Guggenheim Capital LLC lifted its position in Insmed by 16.8% during the second quarter. Guggenheim Capital LLC now owns 41,391 shares of the biopharmaceutical company’s stock worth $4,166,000 after buying an additional 5,945 shares during the period.

Wall Street Analysts Forecast Growth

INSM has been the topic of several research reports. Morgan Stanley upped their target price on Insmed from $157.00 to $162.00 and gave the company an “equal weight” rating in a report on Friday, January 30th. Rothschild & Co Redburn started coverage on shares of Insmed in a research report on Thursday, December 4th. They set a “buy” rating and a $263.00 target price for the company. Royal Bank Of Canada upped their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Wolfe Research set a $167.00 price objective on shares of Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $206.04.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.